Patient-Reported Changes in Weight, Appetite, and Lifestyle During Evolocumab Therapy
Journal of Diabesity · 14.02.2026 · 1 (1)
DOI: 10.66381/jod.2026.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabesity, online erschienen am 14.02.2026. Verfasst von Amna Tabassum und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BackgroundEvolocumab is a PCSK9 inhibitor that has demonstrated efficacy in lowering LDL-C levels and in reducing cardiovascular event risk. Even though initial clinical trials have not consistently reported weight change as an adverse effect, anecdotal patient reports show potential changes in body weight associated with its use. Objective To assess patient-reported changes in body weight, appetite, and lifestyle behaviors after initiation of evolocumab using an anonymous online questionnaire. MethodsIt was a cross-sectional, online survey carried out among self-identified current or former users of evolocumab. Participants completed a survey questionnaire regarding weight changes and their timing, appetite, lifestyle modifications, and subjective effects of the drug. Their responses were summarized by using descriptive statistical methods; 95% confidence intervals (CIs) were measured for each proportion, and Fisher’s exact test was later applied for comparing subgroups. Results:After initiating evolocumab, 19 (90%; 95% CI 68–99%) out of 20 respondents conveyed weight changes. Seventeen participants (81%; 95% CI 59–95%) reported weight gain, while 4 (19%; 95% CI 5–41%) experienced weight loss. Weight changes were observed within the first few weeks by 14 individuals (67%; 95% CI 43–85%). Regarding lifestyle behavior, most participants (13/20; 65%) did not perceive any change. Sixteen respondents (84%) noticed a significant impact of evolocumab on their weight, with perceived impact more frequent among those reporting weight gain (88% vs 25%, p = 0.02). 11 respondents (55%) conveyed appetite changes, especially those who disclosed weight gain (59% vs 25%, p = 0.3). Conclusions:An exploratory online survey indicated weight gain after initiating evolocumab, usually early during therapy, and was independent of lifestyle changes. These results highlight the relevance of patient-perceived drug effects on quality of life. This survey supports conducting the prospective studies to evaluate weight-related effects of PCSK9 inhibitors.
Zitieren
APA
Tabassum, A., Khalil, D. T. K., Irshad, D. S. I., Wains, D. A. A., Fatima, D. S., & Hussain, D. Z. (2026). Patient-Reported Changes in Weight, Appetite, and Lifestyle During Evolocumab Therapy. Journal of Diabesity, 1(1). https://doi.org/10.66381/jod.2026.006
Vancouver
Tabassum A, Khalil DTK, Irshad DSI, Wains DAA, Fatima DS, Hussain DZ. Patient-Reported Changes in Weight, Appetite, and Lifestyle During Evolocumab Therapy. Journal of Diabesity. 2026;1(1). doi:10.66381/jod.2026.006
BibTeX
@article{Tabassum2026,
author = {Tabassum, Amna and Khalil, Dr. Tooba Khalil and Irshad, Dr. Soha Irshad and Wains, Dr. Anwar Ahmed and Fatima, Dr. Sana and Hussain, Dr. Zuha},
title = {Patient-Reported Changes in Weight, Appetite, and Lifestyle During Evolocumab Therapy},
journal = {Journal of Diabesity},
year = {2026},
volume = {1},
number = {1},
doi = {10.66381/jod.2026.006}
}
EUVIMED